ACRO Establishing CRO Forum To Interact with TransCelerate BioPharma Inc.

October 27, 2014

Company News Release

The Association of Clinical Research Organizations today announced plans to constitute a CRO Forum

The Association of Clinical Research Organizations today announced plans to constitute a CRO Forum in order to provide a formal mechanism for the CRO industry to furnish input into the work of TransCelerate BioPharma Inc. The CRO Forum, expected to commence operation in January 2015, is open to all CROs and participation is included as a benefit of ACRO membership.

“ACRO welcomes this opportunity to provide meaningful input on TransCelerate projects of interest to the CRO community,” said Ciaran Murray, ACRO Chairman and CEO of ICON plc. “We have maintained a cordial but informal relationship with TransCelerate since its formation in late 2012. As CROs in general, and ACRO members in particular, are often at the forefront of implementing the innovations advanced by TransCelerate’s members, we believe the time is right for more direct interaction. We will be reaching out to the broader CRO community to gauge interest in participating in the Forum.”

The CRO Forum will provide subject matter experts from participating CROs as liaisons to relevant TransCelerate workstreams. Forum representatives shall be kept apprised of workstream developments and furnish a CRO perspective on projects. The CRO Forum’s charter may be accessed here and interested CROs may contact ACRO by email at[email protected] or by phone.

“We are pleased to work with ACRO and the CRO Forum to provide key stakeholder input into our ongoing and future projects,” said Jonathan Zung, PhD, Vice President and Head Global Clinical Sciences and Operations, UCB and Operations Committee Chair for TransCelerate. “We look forward to open dialogue as we shape industry-wide solutions. Beyond the regular interactions between TransCelerate member companies and their CRO partners, the CRO Forum will serve as TransCelerate’s primary method of interaction with the wider CRO industry.”